The use of GLP1RAs, PPARγ agonists like pioglitazone, and dual PPARα/PPARδ agonists like elafibranor hold promise in influencing macrophage polarization, inflammatory pathways, and improving liver histology in NASH. This evidence concerns the gene PPARD and metabolic dysfunction-associated steatohepatitis.